Skip to main content
Matthew Block, MD, Oncology, Rochester, MN

Matthew S Block MD PhD

Gynecologic Cancer, Hematologic Oncology, Melanoma


Physician

Join to View Full Profile
  • 200 1st St SwRochester, MN 55905

  • Phone+1 507-284-2511

Dr. Block is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2008 - 2011
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
  • Mayo Clinic College of Medicine
    Mayo Clinic College of MedicineClass of 2005

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2006 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Clinical Trials: A Significant Part of Cancer Care
    Clinical Trials: A Significant Part of Cancer CareMay 1st, 2025
  • What You Should Know About Ovarian Cancer Vaccines
    What You Should Know About Ovarian Cancer VaccinesNovember 16th, 2024
  • Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
    Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer VaccineNovember 22nd, 2021
  • Join now to see all

Grant Support

  • A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancerMAYO CLINIC JACKSONVILLE2023–2028
  • A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer PlatformTREKKA THERAPEUTICS, LLC2023–2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: